Retail Bank Executes Expanded $1.04M License Renewal for BIO-key Biometric Identity Solution Serving 30M Clients
BIO-key (NASDAQ: BKYI) secured a $1.04M one-year license renewal and expansion from a foreign retail bank on March 3, 2026, a 30% increase versus prior year.
Rhea-AI Summary
BIO-key (NASDAQ: BKYI) secured a $1.04M one-year license renewal and expansion from a foreign retail bank on March 3, 2026, a 30% increase versus prior year. The company reports $2.7M year-end cash and expects receivables and renewals to fund growth internally. Deployment has grown from 7M enrolled clients in 2015 to over 30M today (≈300M fingerprints); the renewal anticipates 5% client enrollment growth and notes ~10,000 bank employees use the fingerprint system.
Positive
- $1.04M license renewal order received
- Renewal value +30% year-over-year
- Year-end cash position of $2.7M
- Deployment scaled to 30M enrolled clients (~300M fingerprints)
- Approximately 10,000 bank employees use BIO-key authentication
Negative
- None.
Details
News Market Reaction – BKYI
On Mar 3, the day this news came out, BKYI closed 5.12% above the previous close.
Data tracked by StockTitan Argus for the Mar 3 session.
Key Figures
- License renewal value
- $1.04M
- One-year biometric license renewal and expansion order from retail bank
- Renewal increase
- 30%
- Year-over-year increase in value of the one-year license renewal
- Year-end cash
- $2.7M
- Year-end 2025 cash position cited as supporting internal growth plans
- Initial enrolled clients
- 7M clients
- Number of bank clients enrolled when deployment began in 2015
- Current enrolled clients
- 30M clients
- Current number of bank clients enrolled in biometric program
- Managed fingerprints
- 300M fingerprints
- Ten fingerprints per client managed for biometric identification
- Employee users
- 10,000 employees
- Bank employees using BIO-key fingerprint tech for daily operations
- Enrollment growth outlook
- 5% growth
- Anticipated client enrollment increase over coming year in renewal
Historical Context
-
Multi-year SIMO agreement to modernize Mozambique national payments security.
-
Citadel Global distribution deal and Mumbai office plan to expand in India.
-
Visualforma partnership securing IAM rollout across 250+ Portuguese organizations.
-
DealFlow Discovery investor presentation announcement and meeting availability.
-
Advance notice of Jan. 28–29 DealFlow Discovery investor conference appearance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
identity and access management (iam) technical
biometric identification medical
know-your-customer (kyc) regulatory
identity proofing technical
biometric platform technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Year-End Cash Position, License Renewal Activity and Receivables Collections Provide Sound Financial Position to Support Growth
HOLMDEL, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a global leader in biometric-centric Identity and Access Management (IAM) solutions, today announced it has secured a
BIO-key also disclosed that based on its year-end cash position of
Michael DePasquale, BIO-key’s Chairman and CEO, commented, “We are extremely encouraged by our growing traction in larger scale deployments which we expect to bolster our financial results and working capital position moving forward. We entered 2026 on a solid financial footing with approximately
The bank’s biometric identification technology deployment has grown from an initial BIO-key rollout of 7M enrolled clients in 2015 to over 30M today. With ten fingerprints enrolled per client, the program now manages more than 300M fingerprints to support fast, consistent bank client identification and verification for in-branch interactions at teller stations, assisted kiosks and ATMs/automated service points. The renewal incorporates anticipated growth of
In addition, approximately 10,000 bank employees use BIO-key’s fingerprint technology to authenticate themselves during daily branch operations and transaction processing, helping the bank enforce strong controls and reduce the risk of unauthorized activity The system is designed to help extend the trust established during client onboarding into everyday banking. As part of the bank’s know-your-customer (KYC) processes, client fingerprints are verified against the national identity verification system. The certainty of that client identity proofing event is then tied to their BIO-key enrollment and used for positive client identification in subsequent interactions. This helps banks maintain a durable chain of trust that strengthens protection against impersonation, account takeover and fraud.
“Identity assurance is becoming the control point for modern banking. As client service and operations become more automated and AI-assisted, it is essential for banks to deploy robust systems to authenticate customer interactions which can be audited. We are proud to support a ‘biometric chain of identity trust’ that helps connect day-to-day interactions, whether automated or in person, back to the bank’s original identity proofing,” said Jim Sullivan, BIO-key’s SVP of Strategy and Chief Legal Officer. “BIO-key is proud to provide a scalable biometric platform that has supported this customer’s extraordinary growth over the last decade.”
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless and passwordless biometric FIDO Passkey and in-person authentication options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts and expand in foreign markets; fluctuations in foreign currency exchange rates; our history of losses; and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
| Engage with BIO-key | ||
| Facebook – Corporate: | https://www.facebook.com/BIOkeyInternational/ | |
| LinkedIn – Corporate: | https://www.linkedin.com/company/bio-key-international | |
| X – Corporate: | @BIOkeyIntl | |
| X – Investors: | @BIO_keyIR | |
| StockTwits: | BIO_keyIR | |
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com
212-924-9800
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.